Halozyme CEO Helen Torley Executes Pre-Planned Option Exercise & Sale Under Rule 10b5-1

Transaction Overview

On October 8, 2026, Halozyme Therapeutics, Inc. (NASDAQ: HALO) filed a Form 4 disclosing transactions by President and CEO Helen Torley. Between October 6 and October 8, 2026, Dr. Torley exercised stock options to purchase 60,000 shares of common stock at an exercise price of $18.41 per share and subsequently sold all 60,000 acquired shares across multiple tranches at weighted average prices ranging from $107.90 to $113.69.

Key Transaction Details

• Nature of Transactions: Option exercise (Code M) and subsequent open market sales (Code S).
• Rule 10b5-1 Plan: All exercises and sales were executed pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on December 3, 2025.
• Option Grant Details: The exercised options originated from a February 14, 2018 grant expiring in February 2028 with an exercise price of $18.41.
• Total Gross Sale Proceeds: Approximately $6,610,501 (weighted average price of ~$110.18 per share).
• Total Exercise Cost: $1,104,600 (60,000 shares × $18.41).
• Net Pre-Tax Value Realized: ~$5,505,901.

Impact on Ownership

Because the sold shares were newly acquired via option exercises, Dr. Torley's base direct holding of Halozyme common stock remained constant at 767,780 shares. Her remaining vested/unvested option position under this grant was reduced from 81,552 to 21,552 options.

Significance Assessment

The trading significance is categorized as Low. The sales were strictly executed under a pre-established Rule 10b5-1 trading plan to monetize stock options nearing expiration within ~16 months. The transaction represents standard executive compensation realization rather than a discretionary sentiment-driven divestment.